Business Context and Reporting Period
This Form 8-K was filed by Lyell Immunopharma, Inc. on November 16, 2023. The report details a corporate action regarding the repricing of underwater stock options for continuing employees, approved by the Compensation Committee of the Board of Directors.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity compensation adjustments.
Material Changes
The primary material change is the repricing of approximately 23.4 million stock options held by continuing employees. Key details include:
- New Exercise Price: Reduced to $1.87 per share (the closing stock price on November 16, 2023).
- Eligibility: Applied to options with original exercise prices greater than $2.37 under the 2018 and 2021 Equity Incentive Plans.
- Executive Impact: Includes options for CEO Lynn Seely (7.5M shares), CFO Charles Newton (4.818M shares), COO Stephen Hill (2M shares), and CSO Gary Lee (800K shares).
- Retention Conditions: To exercise at the reduced price, holders must remain employed through a "Retention Period" ending on November 15, 2024, or upon a Change in Control, death, or disability.
- Early Exercise Penalty: If exercised before the Retention Period ends, the original higher exercise price applies.
- Vesting Extension: Vesting schedules for unvested shares held by Senior Vice Presidents and above were extended by one year.
Guidance, Outlook, and Risks
Management commentary indicates the repricing was designed to retain and motivate employees without incurring significant stock dilution from new grants or additional cash expenditures. The filing notes that almost all stock options held by continuing employees were previously "underwater" (exercise price above market price). No specific financial guidance or new risk factors were disclosed in this report.
Investor Verification Checklist
- Verify the total number of shares subject to repricing (approx. 23.4 million) against the company's total authorized share count to assess potential dilution.
- Confirm the specific vesting schedules and retention periods for senior executives to understand future equity expense recognition.
- Review the company's cash position to ensure it can sustain operations while relying on equity incentives rather than cash compensation.
- Monitor the stock price relative to the new $1.87 exercise price to gauge the immediate incentive value for employees.